Anzeige
Mehr »
Login
Freitag, 24.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Amazon investiert Millionen in Kernenergie - so können Sie sich früh positionieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PT6W | ISIN: US34417J1043 | Ticker-Symbol:
NASDAQ
23.01.25
19:31 Uhr
0,589 US-Dollar
0,000
0,00 %
Branche
Elektrotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
FOCUS UNIVERSAL INC Chart 1 Jahr
5-Tage-Chart
FOCUS UNIVERSAL INC 5-Tage-Chart
ACCESS Newswire
177 Leser
Artikel bewerten:
(1)

Focus Universal Inc. Announces Appointment of Professor Shivaram Rajgopal to Advisory Board

Finanznachrichten News

ONTARIO, CA AND LOS ANGELES, CA / ACCESSWIRE / December 2, 2024 / Focus Universal Inc. (NASDAQ:FCUV) ("Focus" or the "Company"), a provider of patented hardware and software design technologies for Internet of Things (IoT), 5G and SEC Financial Reporting AI-Driven Automation Software, today announced that Professor Shivaram Rajgopal has been appointed as a member of the Company's Advisory Board.

Professor Shivaram Rajgopal is the Roy Bernard Kester and T.W. Byrnes Professor of Accounting and Auditing at Columbia Business School and serves as the Area Chair for the Accounting Group. Previously, he was a faculty member at Duke University, Emory University, and the University of Washington. Prof. Rajgopal's research spans critical areas such as financial reporting, earnings quality, fraud, executive compensation, and corporate culture, and his work is frequently cited in prominent outlets, including The Wall Street Journal, The New York Times, Bloomberg, Fortune, Forbes, Financial Times, Business Week, and The Economist.

In addition to his research, Professor Rajgopal teaches courses on fundamental analysis of financial statements for investors, managers, and entrepreneurs, as well as a PhD seminar on accounting regulation. He has received numerous prestigious awards, including the American Accounting Association (AAA) Notable Contribution to the Literature Award (2006, 2016, 2018), the Graham and Dodd Scroll Prize from the Financial Analysts Journal (2006, 2016), and the Glen McLaughlin Award for Research in Accounting Ethics (2008, 2012, 2015). Prof. Rajgopal also holds editorial roles, serving as the Departmental Editor for the Accounting track of Management Science and has served as an Associate Editor at the Journal of Accounting and Economics, while previously contributing as an editor for Contemporary Accounting Research and as a board member of The Accounting Review.

Chief Executive Desheng Wang commented, "We are thrilled to welcome Professor Shivaram Rajgopal to our Advisory Board. We are excited to leverage Prof. Rajgopal's extensive expertise and proven track record in accounting and auditing as we continue to advance our AI-driven SEC Financial Reporting Automation Software." Desheng Wang continued, "His strategic insights and guidance will be instrumental in increasing business value for our customers, expanding the global reach of our solutions, and exploring new applications for our unmanned word processing technology beyond SEC financial reporting. Superior financial reporting software has become an urgent necessity in order to lower accounting costs and boost efficiencies."

The financial reporting software market size was valued at USD $13.9 Billion in 2022 and is projected to reach USD $36.6 Billion by 2030, growing at a CAGR of 12.8% from 2024 to 2030. The complexity and volume of financial data, the limiting capabilities of current spreadsheet solutions, the rising cost of compliance, and the expanding demand for such software are the main reasons propelling the growth of the financial reporting software sector.

About Focus Universal:
Focus Universal Inc. is a provider of patented hardware and software design technologies for Internet of Things (IoT) and 5G. The company has developed five disruptive patented technology platforms with 26 patents and patents pending in various phases and eight trademarks pending in various phases to solve the major problems facing hardware and software design and production within the industry today. These technologies combined to have the potential to reduce costs, product development timelines and energy usage while increasing range, speed, efficiency, and security. Focus currently trades on the Nasdaq Markets.

Forward-Looking Statements:
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the "Risk Factors" section of the preliminary prospectus filed with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof and Focus Universal specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

For company inquiries, please contact:
Investor Relations
626-272-3883
ir@focusuniversal.com

SOURCE: Focus Universal Inc.



View the original press release on accesswire.com

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.